LAKECIA WILKINSON: Open Payments
NPI 1497876981 · RICHFIELD, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$374 in 18 payments from 8 companies in 2025. Trend: 2023 $247 · 2024 $310 · 2025 $374
Food & beverage: $374
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $147 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 1 | $46 |
| Neurocrine BioSciences, Inc. | 2 | $44 |
| Lundbeck LLC | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $30 |
| Indivior Inc. | 1 | $16 |
| ABBVIE INC. | 1 | $15 |
Products named: ARISTADA, AUSTEDO XR, Qelbree, INGREZZA, REXULTI, CAPLYTA, SUBLOCADE, VRAYLAR.
Industry payments across UT — which companies pay providers there.
